# US 2020/0370040 A1 · Treatment for parkinsonian patients with mutations in the lrrk2 gene

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0370040 A1
- Document ID: US20200370040A1
- Status: Published application
- Kind: A1
- Application number: 16/769,260
- Filed: 2018-12-06
- Published: 2020-11-26
- Earliest claimed: 2017-12-07
- Assignees: Ramot at Tel-Aviv University Ltd.
- Applicants: Ramot at Tel-Aviv University Ltd.
- Inventors: Daniel OFFEN; Roy RABINOWITZ
- Web page: https://patentgrep.com/patent/US20200370040A1

## CPC

- C12N 15/11: DNA or RNA fragments; Modified forms thereof (DNA or RNA not used in recombinant technology, C07H21/00); {Non-coding nucleic acids having a biological activity}
- A61K 38/465: {acting on ester bonds (3.1), e.g. lipases, ribonucleases}
- A61P 25/16: Anti-Parkinson drugs
- C12N 9/226: {Class 2 CAS enzyme complex, e.g. single CAS protein}
- C12N 15/1137: {against enzymes (viral enzymes C12N15/1131; receptors C12N15/1138)}
- C12N 15/907: {in mammalian cells}
- C12N 9/22: Ribonucleases {[RNase]; Deoxyribonucleases [DNase]}
- C12N 15/90: Stable introduction of foreign DNA into chromosome
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- C12N 2320/30: Special therapeutic applications
- C12N 2320/34: Allele or polymorphism specific uses
- C12N 2800/80: Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A method of treating Parkinson's Disease (PD) characterized by the presence of a mutant allele of leucine-rich repeat kinase 2 (LRRK2) gene in a subject is disclosed. The method comprises administering to the subject a CRISPR-Cas system guide RNA (gRNA) which specifically binds to the mutant allele of said leucine-rich repeat kinase 2 (LRRK2) gene and a CRISPR endonuclease, thereby treating the Parkinson's Disease (PD).

## Claims

### Claim 1

A method of treating Parkinson's Disease (PD) characterized by the presence of a mutant allele of leucine-rich repeat kinase 2 (LRRK2) gene in a subject comprising administering to the subject a CRISPR-Cas system guide RNA (gRNA) which specifically binds to the mutant allele of said leucine-rich repeat kinase 2 (LRRK2) gene and a CRISPR endonuclease, thereby treating the Parkinson's Disease (PD).

### Claim 2 (depends on 1)

The method of claim 1, wherein said mutant allele of leucine-rich repeat kinase 2 (LRRK2) gene comprises the G2019S mutation.

### Claim 3 (depends on 1)

The method of claim 1, wherein said CRISPR endonuclease is Clustered Regularly Interspaced Short Palindromic Repeats from Prevotella and Francisella 1 (Cpf1).

### Claim 4 (depends on 1)

The method of claim 1, wherein the subject is homozygous for a mutation in the LRRK2 gene.

### Claim 5 (depends on 1)

The method of claim 1, wherein the subject is heterozygous for a mutation in the LRRK2 gene.

### Claim 6 (depends on 1)

The method of claim 1, wherein a Protospacer adjacent motif (PAM) sequence utilized by said gRNA comprises said G2019S mutation.

### Claim 7 (depends on 6)

The method of claim 6, wherein said gRNA comprises a nucleic acid sequence as set forth in SEQ ID NO: 3.

### Claim 8 (depends on 1)

The method of claim 1, wherein said gRNA comprises a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 3-7 and 11-21.

### Claim 9 (depends on 8)

The method of claim 8, wherein said gRNA comprises a nucleic acid sequence as set forth in SEQ ID NO: 3 or 4.

### Claim 10

A gRNA which specifically binds to a mutant allele of LRRK2.

### Claim 11 (depends on 10)

The gRNA of claim 10, wherein said mutant allele of LRRK2 comprises the G2019S mutation.

### Claim 12 (depends on 11)

The gRNA of claim 11, wherein a Protospacer adjacent motif (PAM) sequence utilized by said gRNA comprises said G2019S mutation.

### Claim 13 (depends on 12)

The gRNA of claim 12, wherein said gRNA comprises a nucleic acid sequence as set forth in SEQ ID NO: 3.

### Claim 14 (depends on 10)

The gRNA of claim 10, wherein said gRNA comprises a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 4-7 and 3.

### Claim 15 (depends on 14)

The gRNA of claim 14, wherein said gRNA comprises a nucleic acid sequence as set forth in SEQ ID NO: 3 or 4.

### Claim 16 (depends on 10)

The gRNA of claim 10, comprising a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 3-7 and 11-21.

### Claim 17 (depends on 10)

An article of manufacture comprising the gRNA of claim 10 and a CRISPR endonuclease.

### Claim 18 (depends on 17)

The article of manufacture of claim 17, wherein said CRISPR endonuclease is Clustered Regularly Interspaced Short Palindromic Repeats from Prevotella and Francisella 1 (Cpf1).

### Claim 19

(canceled)
